Assessing the most appropriate duration of dual antiplatelet therapy after coronary stenting

August 30, 2011 in Cardiology

A randomised multicentre open-label study evaluating the efficacy and safety of prolonged antiplatelet therapy in patients with coronary disease has found that 24 months' duration of dual therapy is no better than six months DAPT in preventing adverse cardiac events.

However, the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) also found a consistently greater risk of in the 24-month dual group according to all prespecified bleeding definitions, including the recently proposed Bleeding Academic Research Consortium classification. The need for transfusion was also increased in the longer treatment group.

The results, said investigator Dr Marco Valgimigli from the University Hospital of Ferrara, Italy, "question the validity of current - which were based on registry data - that at least 12 months' dual antiplatelet therapy should be pursued after implantation of a drug-eluting stent.

"While we cannot exclude the possibility that a smaller than previously anticipated benefit may still exist in prolonging therapy with clopidogrel for several months after coronary stenting, our study clearly shows that the benefit to risk ratio of prolonged therapy has been over-emphasised."

The PRODIGY study was a 4-by-2 randomised, three-centre open-label clinical trial designed to assess the efficacy and safety of prolonged clopidogrel therapy for up to 24 months in all-comer patients receiving a balanced combination of drug-eluting stents (with various anti-intimal hyperplasia potency and belonging to both first and second generation). Patients were 18 years or older with chronic stable or , including non-ST-elevation and ST-elevation .

More than 2000 patients scheduled for elective, urgent or emergency were randomly assigned in a 1:1:1:1 fashion to one of four stent types: everolimus-eluting stent, paclitaxel-eluting stent, zotarolimus-eluting stent or third-generation thin-strut bare metal stent. Randomisation to the four different types, said Dr Valgimigli, was justified by the different safety profile of each, which was meant to ensure that patients in the two main study groups (six versus 24 month dual antiplatelet therapy) received exactly the same stent types. At 30 days, patients in each stent group were then further randomised to either six or 24 months of dual antiplatelet treatment.

The primary objective of the study was to assess whether 24-month dual antiplatelet treatment, consisting of clopidogrel and aspirin after coronary stenting, was associated with a lower cumulative incidence of all-cause mortality, non-fatal myocardial infarction or cerebrovascular accident (the primary outcome) than six-month dual therapy.

Results showed that the cumulative risk of the primary outcome at two years was 10.1% with the 24-month treatment, and 10.0% with the six-month (HR 0.98; 95% CI 0.74-1.29; P=0.91). The individual risks of death, myocardial infarction, cerebrovascular accident or stent thrombosis did not differ between the two groups.

Among the patients receiving long-term dual antiplatelet therapy, there was a roughly two-fold greater risk of type 5, 3 or 2 bleeding events (HR 2.17, 95% CI 1.44-3.22; p=0.00018) as well as type 5 or 3 bleeding events (HR 1.78, 95% CI 1.02-3.13; p=0.037) according to the Bleeding Academic Research Consortium classification. The risks of TIMI-defined major bleeding and red blood cell transfusion were also increased in the 24-month clopidogrel group.

Commenting on the implications of the results, Dr Valgimigli said: " While a formal economic analysis will follow, the results of this study have important implications for heathcare expenditure - for this study shows that prolonging therapy with beyond six months is not only associated with no clinical benefit but also with a significant increase in actionable bleeding events requiring re-hospitalisations and multiple diagnostic and therapeutic resources."

Provided by European Society of Cardiology search and more info website

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts
  • What capacitors to use in a Tesla coil...?
    created6 hours ago
  • Work done by us on the spring
    created8 hours ago
  • Surface current density
    created10 hours ago
  • Work done on body moving in a circle
    created14 hours ago
  • Crest or Trough?
    created14 hours ago
  • Origin of magnetism
    created17 hours ago
  • More from Physics Forums - Classical Physics

More news stories

One-fifth of healthy middle-aged men have low-grade murmur

(HealthDay) -- More than one-fifth of healthy middle-aged men have a low-grade systolic heart murmur that confers a nearly five-fold higher risk of future aortic valve replacement (AVR), according to a study ...

Cardiology created 8 hours ago | popularity not rated yet | comments 0

New device allows pacemaker patients to safely undergo MRIs

For many, it's a medical conundrum: The very pacemaker keeping their heart in rhythm prevents them from undergoing an MRI to diagnose other ailments, because interaction between the two devices could prove deadly.

Cardiology created 8 hours ago | popularity not rated yet | comments 0 | with audio podcast

New study should end debate over magnesium treatment for preventing poor outcome after haemorrhagic stroke

An international randomised trial and meta-analysis published Online First in The Lancet should put an end to the debate about the use of intravenous magnesium sulphate to prevent poor outcomes after haemorrhagic stroke. The in ...

Cardiology created 14 hours ago | popularity not rated yet | comments 0

Low vitamin D in diet increases stroke risk in Japanese-Americans

Japanese-American men who did not eat foods rich in vitamin D had a higher risk of stroke later in life, according to results of a 34-year study reported in Stroke, an American Heart Association journal.

Cardiology created May 24, 2012 | popularity not rated yet | comments 0

Clot buster seems to help up to 6 hours after stroke

(HealthDay) -- The largest study of its kind finds that stroke patients benefit from a clot-busting drug even six hours after a stroke, suggesting that the current recommended 4.5-hour limit could be expanded.

Cardiology created May 24, 2012 | popularity not rated yet | comments 0


Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse

(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...

Tongue analysis software uses ancient Chinese medicine to warn of disease

For 5,000 years, the Chinese have used a system of medicine based on the flow and balance of positive and negative energies in the body. In this system, the appearance of the tongue is one of the measures used to classify ...

Cancer may require simpler genetic mutations than previously thought

Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...

Skp2 activates cancer-promoting, glucose-processing Akt

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.

Inherited DNA change explains overactive leukemia gene

A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.

Early physical therapist treatment associated with reduced risk of healthcare utilization and reduced overall healthcare

A new study published in Spine shows that early treatment by a physical therapist for low back pain (LBP), as compared to delayed treatment, was associated with reduced risk of subsequent healthcare utilization and lower ...